Baseline characteristics and treatment during 3-year period stratified by disease activity pattern
| pLQ n: 59 | pRR n: 305 | pCA n: 34 | Mixed n: 518 | P values | |
| Baseline characteristics | |||||
| Female sex, n(%) | 47 (79.7) | 285 (93.4) | 32 (94.1) | 471 (90.9) | 0.007 |
| Age, years, median (IQR) | 40 (17) | 36 (17) | 40.5 (27) | 37 (20) | 0.10 |
| Disease duration, years, median (IQR) | 2 (8) | 2 (7) | 2 (10.3) | 2 (6) | 0.85 |
| M-SLEDAI at baseline, median (IQR) | 0 | 2 (4) | 4 (4) | 0 (4) | <0.001 |
| SLEDAI at baseline, median (IQR) | 0 (2) | 4 (4.5) | 4.5 (6.5) | 2 (6) | <0.001 |
| PGA at baseline, median (IQR) | 0 (0.5) | 1 (1) | 1 (1.5) | 1 (1.5) | <0.001 |
| African American, n(%) | 8 (13.6) | 132 (43.3) | 21 (61.8) | 195 (37.6) | <0.001 |
| Caucasian, n(%) | 48 (81.4) | 151 (49.5) | 13 (38.2) | 286 (55.2) | <0.001 |
| Education>12 years, n(%) | 46 (78) | 180 (59.2) | 18 (52.9) | 321 (62.3) | 0.035 |
| Smoking at baseline, n(%) | 4 (6.8) | 37 (12.1) | 9 (26.5) | 88 (17) | 0.02 |
| Combined family Income $, n(%) | |||||
| <30 000 | 12 (20.7) | 107 (35.9) | 17 (50) | 159 (31.6) | |
| 30 000–65 000 | 15 (25.9) | 91 (30.5) | 7 (20.6) | 167 (33.2) | 0.05 |
| ≥65 000 | 31 (53.4) | 100 (33.5) | 10 (29.4) | 177 (35.2) | |
| Treatment during 3 years | |||||
| Prednisone, n(%) | |||||
| Ever received | 36 (61) | 243 (79.7) | 23 (67.6) | 375 (72.4) | 0.009 |
| ≥75% of visits | 18 (30.5) | 182 (59.7) | 18 (52.9) | 249 (48.1) | <0.001 |
| Hydroxychloroquine, n (%) | |||||
| Ever received | 43 (72.9) | 243 (79.7) | 20 (58.8) | 397 (76.7) | 0.04 |
| ≥75% of visits | 40 (67.8) | 184 (60.3) | 15 (44.1) | 309 (59.7) | 0.17 |
| Immunosuppressive drug treatment, n (%) | |||||
| Ever received | 19 (32.2) | 165 (54.1) | 14 (41.2) | 257 (49.6) | 0.01 |
| ≥75% of visits | 14 (23.7) | 89 (29.2) | 10 (29.4) | 143 (27.6) | 0.85 |
M-SLEDAI:, Modified SLEDAI; PGA, physician’s global assessment; SLE, systemic lupus erythematosus; SLEDAI, SLE Disease Activity Index.